NCT03177174已完成不适用
the General Hospital of PLA
Luo yanrong1 个研究点 分布在 1 个国家目标入组 150 人开始时间: 2017年6月12日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 150
- 试验地点
- 1
- 主要终点
- changes in toxic reaction
研究概览
简要总结
This study was to evaluate the efficacy ,toxic reaction and safety of different chemotherapy combined with radiotherapy on patients with locally advanced nasopharyngeal carcinoma.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients > 18, <70 years old, with locally advanced nasopharyngeal carcinoma.
排除标准
- •patients who had accepted radiotherapy before patients with any ather types of cancer
研究组 & 干预措施
Docetaxel
Active Comparator
干预措施: Docetaxel (Drug)
Cisplatin
Active Comparator
干预措施: Cisplatin (Drug)
DocetaxelCisplatin
Active Comparator
Cisplatin combined with Docetaxel
干预措施: Cisplatin (Drug)
DocetaxelCisplatin
Active Comparator
Cisplatin combined with Docetaxel
干预措施: Docetaxel (Drug)
结局指标
主要结局
changes in toxic reaction
时间窗: 5 years
incidence rate of the toxic reaction between three groups
次要结局
- over survival(5 years)
研究者
Luo yanrong
Clinical Doctor
Chinese PLA General Hospital
研究点 (1)
Loading locations...
相似试验
尚未招募
1 期
Combination Chemotherapy With Pazopanib in Children and Adolescents With Relapsed/Refractory Solid TumorsRelapsed Pediatric Solid TumorRefractory Pediatric Solid TumorNCT03628131Samsung Medical Center46
已完成
2 期
Neoadjuvant Therapy of GP Chemotherapy Combined With Tislelizumab in Locoregionally Advanced NPCNasopharyngeal CarcinomaNCT04833257Sun Yat-sen University63
进行中（未招募）
2 期
Phase II Study of Combined Chemotherapy With Arsenic Trioxide in Stage 4/M NeuroblastomaNeuroblastomaNCT03503864Yang Li80
已完成
3 期
A phase III randomized study with Paclitaxel (Taxol) and Gemcitabine or Vinorelbine in patients with stage IIIBw - IV non-operable non-small cell lung cancer (NSCLC), performance status (PS) 0,1.Non-Small Cell Lung CancerACTRN12609000946213Hellenic Cooperative Oncology Group441
进行中（未招募）
3 期
Neoadjuvant and Adjuvant Tislelizumab for Nasopharyngeal CarcinomaNasopharyngeal CarcinomaNCT05211232Sun Yat-sen University450